Skip to content
Review

Relationship Between miRNA and Neurodegenerative Diseases Such as Alzheimer's disease, Parkinson's, Huntington's disease, Amyotrophic Lateral Sclerosis.

Jul 2026 · Mini-Reviews in Medical Chemistry · Vol 26 · 0 citations
Medicine

TL;DR

Data from the last 5 years on neurodegenerative diseases associated with miRNA dysregulation is examined, including Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Huntington's Disease (HD).

Abstract

The regulatory roles of miRNAs on CNS homeostasis, neuronal differentiation, and synaptic plasticity make these molecules indispensable for healthy brain functions. miRNA dysregulation, by triggering abnormal neurodevelopment, has a critical impact on the etiology and progression of neurodegenerative diseases. MicroRNAs (miRNAs) are short, single-stranded, non-coding ribonucleic acid (RNA) molecules, 18 to 24 nucleotides long. They play a role in posttranscriptional gene regulation by binding to complementary sequences on messenger RNA (mRNA), thereby promoting mRNA degradation or preventing translation into protein. MiRNAs are essential regulators of the genome because they bind targets and alter gene expression. MiRNA biogenesis and functions are tightly regulated, and their dysregulation is associated with various diseases, including cancer, cardiovascular diseases, and neurodegenerative disorders. In particular, disruption of the Blood-Brain Barrier in neurodegenerative diseases allows molecules to leak into the bloodstream, enabling the detection of miRNAs in other body fluids and making these fluids potential biomarker sources. In this context, miRNAs can be measured in blood, cerebrospinal fluid, and other biological samples. It has significant potential for early diagnosis, disease progression monitoring, and evaluation of treatment efficacy. In this review, the relationship between MiRNAs and neuronal degeneration diseases was evaluated. In this review, prepared in light of the current literature scanned through the PubMed database, we examined data from the last 5 years (2021-2026) on neurodegenerative diseases associated with miRNA dysregulation, including Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Huntington's Disease (HD).

View source

Similar papers

Review 2026

Role of microRNAs in major brain diseases, focusing on neuroinflammation and neuronal apoptosis

MicroRNAs are non-coding small RNA molecules that play a significant role in regulating gene expression. Increasing lines of evidence have highlighted the microRNA dysregulation and neuroinflammation-associated apoptosis in common brain diseases, including Parkinson’s disease, Alzheimer’s disease, epilepsy, traumatic b...

Nimra Aziz, Ghulam Hussain, Q. Abbas · 0 citations
Review 2026

Epigenetic modulators as therapeutics for neurodegenerative disorders/Alzheimer's disease.

Overall, epigenetic modulators present a promising therapeutic approach for neurodegeneration, and continued research integrating various assays like DNA methylation analysis, histone modification analysis, non-coding RNA analysis, neuroinflammation analysis, and functional and behavioral assays in AD models is signifi...

Debojyoti Halder, Denish Prajapati, Tonmoy Banerjee et al. · 0 citations
Review Open access Sep 2026

MicroRNAs as Diagnostic Biomarkers for Alzheimer’s Disease and Related Dementias

This review delineates the critical functions of specific miRNAs in orchestrating the three primary pathological pillars of AD: amyloid-β (Aβ) buildup, chronic neuroinflammation, and systemic oxidative stress.

Manivannan Subramanian, Aditi Singh, Amit Singh · 0 citations
Review Open access Sep 2026

MicroRNAs in immune-related diseases: mechanism, functions and therapeutic perspectives

The biogenesis and biological functions of miRNAs are discussed and their regulatory roles in the pathogenesis of rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, multiple sclerosis, psoriasis, systemic lupus erythematosus, and atopic dermatitis are examined.

T. Tunç, Serap Yaman Ozer, Sema Mısır · 0 citations
Review Open access Aug 2026

MicroRNA-phytochemical interactome targeting thioredoxin-interacting protein: a narrative review at the nexus of RNA therapeutics, cancer biology, and metabolic regulation

This narrative review discussed emerging trends on phytochemical-mediated regulation of TXNIP-associated miRNAs, including miR-148b, miR-33a/b, miR-17-5p, miR-224, and miR-20a, with particular emphasis on the conserved miRNA seed region as the principal determinant of target recognition.

Peter Chinedu Agu, P. Aja, C. Ofor et al. · 0 citations
Review Open access Sep 2026

MicroRNAs in polyglutamine diseases: Mechanistic insights, circulating biomarkers, and emerging microRNA-based therapeutic strategies.

This review synthesizes recent advances in miRNA dysregulation across all nine PolyQ diseases, focusing on studies published since 2019, and highlights therapeutic progress, including the preclinical efficacy of adeno-associated virus (AAV)-delivered artificial miRNAs and emerging exosome-based platforms that target mu...

Yang Liu, Ying Cui, Miao Sun et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.